Mouse CNR1 (Cannabinoid Receptor 1, Brain) ELISA Kit

Este producto es parte de CNR - Cannabinoid Receptor
Product Graph
Contáctenos para saber el precio

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.

935106861
info@markelab.com
name
Mouse CNR1 (Cannabinoid Receptor 1, Brain) ELISA Kit
category
ELISA Kits
provider
FineTest
reference
EM0936
tested applications
ELISA

Documents del producto

Instrucciones
Descargar
Data sheet

Product specifications

Category
ELISA Kits
Reactivity
Mouse
Detection Method
Colorimetric
Assay Data
4 hours
Assay Type
Sandwich ELISA, Double Antibody
Test Range
0.313-20ng/ml
Sensitivity
0.188ng/ml
Size 1
96T
Tested Applications
ELISA
Sample Type
Serum, Plasma, Cell Culture Supernatant, cell or tissue lysate, Other liquid samples
Availability
Shipped within 10-14 working days.
Storage
2-8 °C for 12 months
UniProt ID
O88689
Alias
CNR1,THC receptor,CB-R,Cann6,SKR6R,CB1R,Cann7,CB1, CB1A, CB1K5,CNR
Background
Elisa kits for CNR1
Status
RUO

Cannabinoid Receptor 1 (CNR1), commonly known as CB1, is one of the two primary receptors of the endocannabinoid system (ECS), a lipid signaling system that regulates homeostasis and diverse physiological processes. CB1 is predominantly expressed in the central nervous system (CNS), including regions like the hippocampus, cerebellum, and basal ganglia, where it modulates synaptic transmission and neuronal activity. CB1 interacts with endocannabinoids like anandamide (AEA) and 2-arachidonoylglycerol (2-AG), as well as exogenous cannabinoids like tetrahydrocannabinol (THC), the psychoactive compound in cannabis. Through this interaction, CB1 plays a key role in regulating pain perception, mood, appetite, memory, and motor control. In the periphery, CB1 expression in tissues such as the liver, adipose tissue, and pancreas contributes to energy metabolism, glucose homeostasis, and lipid storage, linking CB1 to obesity and metabolic disorders. Overactivation of CB1 signaling is associated with conditions like addiction, anxiety, and depression, as well as non-alcoholic fatty liver disease (NAFLD) and insulin resistance. CB1 antagonists, such as rimonabant, have been explored for treating obesity and metabolic syndrome, although their psychiatric side effects limit widespread use. The ECS, particularly CB1, continues to be a focus of intense research for developing safer therapeutics targeting pain, neurological disorders, and psychiatric conditions, including post-traumatic stress disorder (PTSD) and epilepsy.

Related Products

EH2848

Human CNR1 (Cannabinoid Receptor 1, Brain) ELISA Kit

Ver Producto
EM0936

Mouse CNR1 (Cannabinoid Receptor 1, Brain) ELISA Kit

Ver Producto
FNab01244

CNR1 antibody

Ver Producto